Aerie Pharmaceuticals INC Stock: price and directors' dealings · United States · SEC (Form 4)

About Aerie Pharmaceuticals INC

Aerie Pharmaceuticals Inc. was a U.S.-based ophthalmic pharmaceutical company listed on the NASDAQ in the United States under ticker AERI before being acquired by Alcon. The company was built around the discovery, development, and commercialization of therapies for eye diseases, with a particular emphasis on glaucoma and ocular hypertension. Its business model was rooted in specialty pharma economics: concentrated R&D, a narrowly focused therapeutic franchise, and a goal of converting differentiated science into approved products with meaningful commercial potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm?utm_source=openai)) Founded in the early 2010s, Aerie established its headquarters in Durham, North Carolina, placing it within one of the United States’ strongest life-science hubs. Over time, the company evolved from a development-stage ophthalmology name into a commercial-stage player. Its best-known products were Rhopressa (netarsudil ophthalmic solution), indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of netarsudil and latanoprost. These products became the core of Aerie’s glaucoma franchise and the main proof points of its technology platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1337553/000162828019013540/aeri10-qx93019.htm?utm_source=openai)) From a competitive standpoint, Aerie differentiated itself through a highly specialized ophthalmology focus and its ROCK-inhibitor-based mechanism of action. That specialization gave it a distinct position versus larger diversified pharma companies, which typically compete with broader portfolios but less targeted innovation. Aerie also pursued international expansion through licensing and commercialization partnerships, aiming to extend the reach of Rhopressa and Rocklatan beyond the U.S. while leveraging partners’ regional infrastructure. ([nasdaq.com](https://www.nasdaq.com/press-release/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressar-and-rocklatanr?utm_source=openai)) Beyond glaucoma, the company continued to invest in retinal-disease programs and sustained-release ophthalmic technologies, reflecting an ambition to build a broader eye-care pipeline. Even so, the defining recent corporate event was Alcon’s acquisition of Aerie, which underscored the strategic value of its commercial assets and R&D capabilities. For investors, Aerie is best understood as a specialist U.S. NASDAQ ophthalmology company that successfully translated niche innovation into a valuable franchise attractive to a global eye-care leader. ([alcon.com](https://www.alcon.com/media-release/alcon-acquire-aerie-pharmaceuticals-inc-enhancing-its-ophthalmic-pharmaceutical/?utm_source=openai))